Healthcare costs associated with liso-cel in an inpatient versus outpatient setting for MCL 

Tycel Phillips, MD, City of Hope, Duarte, CA, discusses a study comparing healthcare costs associated with lisocabtagene maraleucel (liso-cel) in an inpatient versus outpatient setting for the treatment of mantle cell lymphoma (MCL). The study highlights potential cost savings with liso-cel if administered in an outpatient setting compared to the typical inpatient costs associated with CAR-T in MCL. Although some patients experienced severe events necessitating inpatient care, outpatient administration was significantly associated with reduced costs. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.